<DOC>
	<DOCNO>NCT01115920</DOCNO>
	<brief_summary>This first study MTP-131 ( Bendavia™ ) human . The objective study evaluate safety , tolerability , pharmacokinetics escalate single intravenous infusion dose MTP-131 .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics ( PK ) Intravenous ( IV ) Infusion MTP-131 ( Bendavia™ ) Healthy Adults</brief_title>
	<detailed_description>The primary objective study evaluate safety tolerability MTP-131 healthy volunteer follow single intravenous infusion . The secondary objective evaluate pharmacokinetics MTP-131 . This double-blind , placebo-controlled , randomized trial . A total 40 eligible subject enrol randomized 3:1 active placebo ratio total 5 treatment group 8 volunteer . As far logistically possible , treatment group similar number male female volunteer . After last subject cohort complete day 3 clinical assessment stop rule meet accord Safety Review Board decision , next cohort commence .</detailed_description>
	<criteria>Healthy adult male female age ≥18 year age sign informed consent . Women postmenopausal surgically sterile must negative serum pregnancy test screening within 24 hour treatment agree use effective contraception 30 day follow study . Clinically significant laboratory abnormality , Clinically significant abnormality physical examination , BMI le 18 kg/m2 great 32 kg/m2 , Any disease condition might compromise cardiovascular , hematological , renal , hepatic , pulmonary ( include chronic asthma ) , endocrine ( e.g. , diabetes ) , central nervous , gastrointestinal ( include ulcer ) system , History seizures epilepsy , History serious mental illness , Participant unrelated research involve investigational product within 30 day plan date drug administration , Positive serology HIV 1 , HIV 2 , HBsAg , HCV , Fever great 37.5°C time plan dosing , Suspicion recent history alcohol substance abuse , Donated blood blood product within past 30 day , Women pregnant breastfeeding , Employee family member investigational site , Subjects currently smoke cigarette , cigar , pipe chew tobacco product , Subjects either unwilling agree refrain use find use : 1 . Alcohol , caffeine , xanthinecontaining food beverage , nicotine product overthecounter medication exception Tylenol 24 hour prior dose throughout confinement period 2 . Prescription medication 14 day prior 7 day post treatment 3 . Oral contraceptive without concomitant use doublebarrier contraceptive ( condom , diaphragm spermicide ) period 7 day prior 30 day post treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Drug Safety</keyword>
	<keyword>Clinical Trial , Phase I</keyword>
	<keyword>Nontherapeutic Human Experimentation</keyword>
	<keyword>Heading Pharmacokinetics</keyword>
	<keyword>Phase I Safety Tolerability</keyword>
</DOC>